Keywords: impact, propecia, merck, co, assessed, finasteride, 1mg
Impact Of Propecia On Merck & Co Assessed
Article | 28 January 1998
With Merck & Co's Propecia (finasteride 1mg) for the treatment of malepattern baldness now on drugstore shelves (Marketletter January 5 & 12), it appears ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
